Table 2.
Unadjusted hazard ratios (HR) for all-cause mortality in univariable analyses.
| Unadjusted HR (95% CI) | P value | |
|---|---|---|
| Age | 1.00 (0.98–1.03) | 0.644 |
| Male sex | 0.50 (0.29–0.88) | 0.016 |
| BMI | 1.01 (0.93–1.09) | 0.843 |
| NYHA functional class ≥ III | 3.12 (1.73–5.62) | 0.000 |
| Heart rate | 1.02 (1.0–1.04) | 0.083 |
| NT-proBNP (per 50 pg/mL) | 1.02 (1.01–1.02) | 0.000 |
| Pericardial effusion | 1.98 (1.14–3.44) | 0.016 |
| Patchy pattern of lung perfusion | 2.47 (1.32–4.63) | 0.005 |
| mRAP | 1.07 (1.02–1.11) | 0.004 |
| mPAP | 1.03 (1.01–1.04) | 0.001 |
| CI | 0.55 (0.38–0.80) | 0.002 |
| TPR | 1.00 (1.00–1.00) | 0.001 |
| PAH-targeted drug | 1.40 (0.70–2.79) | 0.339 |
| Anticoagulants | 0.62 (0.36–1.07) | 0.087 |
| Calcium channel blockers | 0.78 (0.38–1.60) | 0.492 |
| Diuretics | 21.21 (0.02–27013.42) | 0.402 |
| Digoxin | 1.19 (0.58–2.46) | 0.642 |
| RV anteroposterior dimension | 1.06 (1.02–1.09) | 0.003 |
| TSH | 1.13 (1.02–1.24) | 0.016 |
| Endothelin | 1.44 (1.14–1.82) | 0.002 |
| Blood urea nitrogen | 1.32 (1.16–1.51) | 0.000 |
| Creatinine | 1.0 (1.0–1.01) | 0.510 |
| Alkaline phosphatase | 1.0 (1.0–1.01) | 0.180 |
| D-dimer | 1.00 (1.0–1.01) | 0.247 |
CI, confidence interval; BMI, body mass index; NYHA, New York Heart Association; NTproBNP, serum N-terminal pro B-type natriuretic peptide; mRAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; RV: right ventricular; CI, cardiac index; TPR, total pulmonary resistance; TSH, thyroid-stimulating hormone.